Non-cirrhotic portal vein thrombosis (ncPVT) most often occurs in the setting of intraabdominal proinflammatory processes. Less often, ncPVT may result from primary hematologic thrombophilia (most commonly JAK2V617F). Although these etiologic categories are pathophysiologically distinct, they are treated similarly using anticoagulation. We conducted a retrospective assessment of outcomes among ncPVT patients harboring JAK2V617F, and compared them to outcomes among patients with other etiologies for ncPVT, to determine whether anticoagulation alone is adequate therapy for JAK2V617F associated PVT. Outcomes were complete radiographic resolution (CRR) of PVT, recanalization (RC) of occlusive PVT, and development of significant portal hypertension (SPH). Three-hundred-thirty ncPVT patients seen between 1/2000 and 1/2019, including 37 harboring JAK2V617F (JAK2), 203 with other evident etiology (OE) for PVT, and 90 with no evident etiology (NE) for PVT followed for a median 29 months (53, 21, and 32 months respectively). Outcomes among the JAK2 cohort were dismal relative to the other groups. CRR rates were 8%, 31%, and 55% for the JAK2, NE, and OE cohorts respectively (multivariable HR JAK2:OE = 0.15 (0.05, 0.49), p = 0.0016). RC rates were 16%, 33%, and 49% for the JAK2, NE, and OE cohorts respectively (multivariable HR for RC JAK2:OE = 0.24 (0.09, 0.63), p = 0.0036). SPH rates were 49%, 32%, and 17% for the JAK2, NE, and OE cohorts respectively (multivariable HR for SPH JAK2:OE = 1.23 (0.62, 2.42), p = 0.5492). Given the strikingly poor outcomes among patients harboring JAK2V617F, anticoagulation alone does not appear to be adequate therapy for this cohort. Further investigation into thrombolysis and/or thrombectomy as an adjunct to anticoagulation is merited in this high-risk group.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Intagliata NM, Caldwell SH, Tripodi A (2019) Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology 156(6):1582–1599
Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M et al (2009) JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113(22):5617–5623
How J, Zhou A, Oh ST (2017) Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease. Ther Adv Hematol 8(3):107–118
Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R (2009) The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 113(21):5246–5249
Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J et al (2010) Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 51(1):210–218
Klinger C, Riecken B, Schmidt A, De Gottardi A, Meier B, Bosch J et al (2017) Transjugular local thrombolysis with/without TIPS in patients with acute non-cirrhotic, non-malignant portal vein thrombosis. Dig Liver Dis 49(12):1345–1352
Brookmeyer R (1982) A confidence interval for the median survival time. Biometrics 38(1):29–41
Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I et al (2016) Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 14(12):1572–1611
Iwakiri Y (2014) Pathophysiology of portal hypertension. Clin Liver Dis 18(2):281–291
Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F (2006) Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91(2):169–175
Hobbs CM, Manning H, Bennett C, Vasquez L, Severin S, Brain L et al (2013) JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood 122(23):3787–3797
Edelmann B, Gupta N, Schnoeder TM, Oelschlegel AM, Shahzad K, Goldschmidt J et al (2018) JAK2-V617F promotes venous thrombosis through beta1/beta2 integrin activation. J Clin Invest 128(10):4359–4371
Wang MQ, Guo LP, Lin HY, Liu FY, Duan F, Wang ZJ (2010) Transradial approach for transcatheter selective superior mesenteric artery urokinase infusion therapy in patients with acute extensive portal and superior mesenteric vein thrombosis. Cardiovasc Intervent Radiol 33(1):80–89
Malkowski P, Pawlak J, Michalowicz B, Szczerban J, Wroblewski T, Leowska E et al (2003) Thrombolytic treatment of portal thrombosis. Hepatogastroenterology 50(54):2098–2100
Hollingshead M, Burke CT, Mauro MA, Weeks SM, Dixon RG, Jaques PF (2005) Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol 16(5):651–661
Hall TC, Garcea G, Metcalfe M, Bilku D, Dennison AR (2011) Management of acute non-cirrhotic and non-malignant portal vein thrombosis: a systematic review. World J Surg 35(11):2510–2520
Turnes J, Garcia-Pagan JC, Gonzalez M, Aracil C, Calleja JL, Ripoll C et al (2008) Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol 6(12):1412–1417
Sankar K, Stein BL (2018) Do all patients with polycythemia vera or essential thrombocythemia need cytoreduction? J Natl Compr Canc Netw 16(12):1539–1545
Finazzi G, De Stefano V, Barbui T (2018) Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018. Blood Cancer J 8(7):64
The authors wish to acknowledge the support of the Biostatistics Shared Resource Facility, Icahn School of Medicine at Mount Sinai, and NCI Cancer Center Support Grant P30 CA196521-01.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Conflict of interest
The authors have no relevant conflicts of interest to report.
This article does not contain any studies with human participants or animals performed by any of the authors. This article describes a retrospective study which did require review of patient medical records. As such, this study was approved by the Program for the Protection of Human Subjects (PPHS) and the Institutional Review Board (IRB) of the Mount Sinai Hospital.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Naymagon, L., Tremblay, D., Zubizarreta, N. et al. Portal vein thrombosis patients harboring JAK2V617F have poor long-term outcomes despite anticoagulation. J Thromb Thrombolysis (2020). https://doi.org/10.1007/s11239-020-02052-4
- Portal vein thrombosis (PVT)
- Splanchnic vein thrombosis (SVT)
- Myeloproliferative neoplasm (MPN)